Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Regen BioPharmaRGBP +55.00% Debt-to-Equity is -0.18 as of Mar. 2026. The stock has 7 warning signs investors should review. Among 966 Biotechnology companies, Regen BioPharma ranks worse than 103519.57% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Regen BioPharma's Debt-to-Equity or its related term are showing as below:
RGBP'
s Debt-to-Equity Range Over the Past 10 Years
Min: -1.58 Med: -0.17 Max: -0.04
Current: -0.18
During the past 13 years, the highest Debt-to-Equity Ratio of Regen BioPharma was -0.04. The lowest was -1.58. And the median was -0.17.
RGBP's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.16
vs RGBP: -0.18
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Regen BioPharma Debt-to-Equity Related Terms
Regen BioPharma Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Regen BioPharma's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RGBP vs SIGY, ENDV, CNBX: Debt-to-Equity Comparison
For the Biotechnology subindustry, Regen BioPharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regen BioPharma Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regen BioPharma's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Regen BioPharma's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regen BioPharma (RGBP) has a Debt-to-Equity of -0.18 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Regen BioPharma and its competitors. According to the industry distribution chart, Regen BioPharma ranks #999999 out of 966 companies in the Biotechnology industry.
Is Regen BioPharma's Debt-to-Equity too high?
Regen BioPharma's current Debt-to-Equity is -0.18. Based on the distribution chart, Regen BioPharma ranks #999999 out of 966 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Regen BioPharma's Debt-to-Equity compare to SIGY and ENDV?
According to the Biotechnology industry distribution chart, Regen BioPharma ranks #999999 out of 966 companies for Debt-to-Equity. This places Regen BioPharma in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Regen BioPharma and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regen BioPharma's current Debt-to-Equity is -0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regen BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Regen BioPharma (RGBP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.02, compared to a current price of $0.00 — trading 99.2% below its estimated fair value. The current Debt-to-Equity is -0.18. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Regen BioPharma (RGBP), the current Debt-to-Equity is -0.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regen BioPharma Inc is a USA-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II are cellular therapies designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGBP has been successfully added to your 
